These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 17436027)

  • 41. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. A survey of standards and guidelines for cost-effectiveness analysis in health care.
    Stewart A; Schmier JK; Luce BR
    Am Heart J; 1999 May; 137(5):S53-61. PubMed ID: 10220598
    [No Abstract]   [Full Text] [Related]  

  • 42. [Hungarian psychiatry in the light of the Hungarian Presidency of the Council of the European Union].
    Kurimay T
    Psychiatr Hung; 2010; 25(6):483-92. PubMed ID: 21300996
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Health law and policy in the European Union.
    Greer SL; Hervey TK; Mackenbach JP; McKee M
    Lancet; 2013 Mar; 381(9872):1135-44. PubMed ID: 23541054
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Seeing the NICE side of cost-effectiveness analysis: a qualitative investigation of the use of CEA in NICE technology appraisals.
    Bryan S; Williams I; McIver S
    Health Econ; 2007 Feb; 16(2):179-93. PubMed ID: 16960851
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Establishing the health and economic impact of influenza vaccination within the European Union 25 countries.
    Ryan J; Zoellner Y; Gradl B; Palache B; Medema J
    Vaccine; 2006 Nov; 24(47-48):6812-22. PubMed ID: 17034909
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cardiac resynchronization therapy (CRT) in heart failure--a model to assess the economic value of this new medical technology.
    Banz K;
    Value Health; 2005; 8(2):128-39. PubMed ID: 15804321
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Facts, fallacies, and politics of comparative effectiveness research: Part I. Basic considerations.
    Manchikanti L; Falco FJ; Boswell MV; Hirsch JA
    Pain Physician; 2010; 13(1):E23-54. PubMed ID: 20119474
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Health technology assessment: a multidisciplinary approach for selecting innovations in the health service].
    Cavallo MC
    G Ital Nefrol; 2013; 30(3):. PubMed ID: 23832477
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Maximizing health through the rapidly developing fields of comparative and cost-effectiveness.
    Annemans L
    J Comp Eff Res; 2012 Nov; 1(6):479-80. PubMed ID: 24236465
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cost and reimbursement of cataract surgery in Europe: a cross-country comparison.
    Fattore G; Torbica A
    Health Econ; 2008 Jan; 17(1 Suppl):S71-82. PubMed ID: 18186033
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Analysis of the effectiveness of an internal hospital bone bank].
    Flören M; Kappe T; Reichel H
    Orthopade; 2007 Jul; 36(7):667-72. PubMed ID: 17522840
    [TBL] [Abstract][Full Text] [Related]  

  • 52. How do we evaluate the economics of health care?
    Kumar S; Williams AC; Sandy JR
    Eur J Orthod; 2006 Dec; 28(6):513-9. PubMed ID: 17035484
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cost-effectiveness of trastuzumab in metastatic breast cancer: mainly a matter of price in the EU?
    Garattini L; van de Vooren K; Curto A
    Health Policy; 2015 Feb; 119(2):212-6. PubMed ID: 25523144
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [QUALICOPC -- primary care study on quality, costs and equity in European countries: the Hungarian branch].
    Rurik I; Boerma WG; Kolozsvári LR; Lánczi LI; Mester L; Móczár C; Schäfer LA; Schmidt P; Torzsa P; Végh M; Gronewegen PP
    Orv Hetil; 2012 Sep; 153(35):1396-400. PubMed ID: 22935433
    [TBL] [Abstract][Full Text] [Related]  

  • 55. UNDERSTANDING VARIATIONS IN RELATIVE EFFECTIVENESS: A HEALTH PRODUCTION APPROACH.
    Towse A; Jonsson B; McGrath C; Mason A; Puig-Peiro R; Mestre-Ferrandiz J; Pistollato M; Devlin N
    Int J Technol Assess Health Care; 2015; 31(6):363-70. PubMed ID: 26837803
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluating health care interventions in the European Union.
    McDaid D; Cookson R;
    Health Policy; 2003 Feb; 63(2):133-9. PubMed ID: 12543526
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Introduction: mass screening, health technology assessment, and health policy in some European countries.
    Oortwijn W; Banta HD; Cranovsky R
    Int J Technol Assess Health Care; 2001; 17(3):269-74. PubMed ID: 11495373
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The novelties of the regulation on health technology assessment, a key achievement for the European union health policies.
    Pisapia A; Banfi G; Tomaiuolo R
    Clin Chem Lab Med; 2022 Jul; 60(8):1160-1163. PubMed ID: 35624072
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cost-effectiveness thresholds: methods for setting and examples from around the world.
    Santos AS; Guerra-Junior AA; Godman B; Morton A; Ruas CM
    Expert Rev Pharmacoecon Outcomes Res; 2018 Jun; 18(3):277-288. PubMed ID: 29468951
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.